Ali Amidi1, Lisa M Wu2, Mads Agerbæk3, Patrick Londin Larsen1, Anders D Pedersen4, Mimi Mehlsen1, Lars Larsen5, Robert Zachariae1. 1. Unit for Psychooncology and Health Psychology, Department of Oncology and Department of Psychology and Behavioural Sciences, Aarhus University Hospital and Aarhus University, Aarhus, Denmark. 2. Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA. 3. Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. 4. Vejlefjord Rehabilitation, Stouby, Denmark. 5. Department of Psychology and Behavioural Sciences, Aarhus University, Aarhus, Denmark.
Abstract
OBJECTIVE: The aim of this study was to determine the prevalence of cognitive impairment (CI) in newly diagnosed and orchiectomized testicular cancer (TC) patients prior to systemic treatment, and to explore biological and psychological correlates. METHODS: Sixty-six TC patients were compared with 25 healthy men on neuropsychological tests and a measure of cognitive complaints. CI status and a global composite score (representing overall neuropsychological performance) were calculated for each participant. Possible psychological (depression, anxiety, stress, and post-traumatic stress symptoms) and biological (cortisol, IL-6, TNF-α, and CRP) correlates and predictors of patients' cognitive functioning were explored. RESULTS: TC patients had lower scores on 6 out of 11 neuropsychological outcomes (p < 0.01) in processing speed, attention, and working memory, verbal learning and memory, and verbal fluency. Prevalence of CI among TC patients was 58%, significantly exceeding the frequency in healthy men (p < 0.01). Patients' cortisol levels predicted overall neuropsychological performance (p = 0.04). Cognitive complaints were associated with IL-6 (p = 0.02) and all psychological distress measures (p < 0.001). CONCLUSIONS: The prevalence of CI in recently orchiectomized TC patients was unexpectedly high with patients performing more poorly than healthy controls on a majority of neuropsychological outcomes. Cortisol is a potential predictor of neuropsychological performance in TC patients prior to cytotoxic treatment.
OBJECTIVE: The aim of this study was to determine the prevalence of cognitive impairment (CI) in newly diagnosed and orchiectomized testicular cancer (TC) patients prior to systemic treatment, and to explore biological and psychological correlates. METHODS: Sixty-six TC patients were compared with 25 healthy men on neuropsychological tests and a measure of cognitive complaints. CI status and a global composite score (representing overall neuropsychological performance) were calculated for each participant. Possible psychological (depression, anxiety, stress, and post-traumatic stress symptoms) and biological (cortisol, IL-6, TNF-α, and CRP) correlates and predictors of patients' cognitive functioning were explored. RESULTS: TC patients had lower scores on 6 out of 11 neuropsychological outcomes (p < 0.01) in processing speed, attention, and working memory, verbal learning and memory, and verbal fluency. Prevalence of CI among TC patients was 58%, significantly exceeding the frequency in healthy men (p < 0.01). Patients' cortisol levels predicted overall neuropsychological performance (p = 0.04). Cognitive complaints were associated with IL-6 (p = 0.02) and all psychological distress measures (p < 0.001). CONCLUSIONS: The prevalence of CI in recently orchiectomized TC patients was unexpectedly high with patients performing more poorly than healthy controls on a majority of neuropsychological outcomes. Cortisol is a potential predictor of neuropsychological performance in TC patients prior to cytotoxic treatment.
Authors: Daniel C McFarland; Meredith Doherty; Thomas M Atkinson; Robin O'Hanlon; William Breitbart; Christian J Nelson; Andrew H Miller Journal: Cancer Date: 2022-04-13 Impact factor: 6.921
Authors: Natalie G Regier; Aanand D Naik; Elizabeth A Mulligan; Ziad S Nasreddine; Jane A Driver; Yvonne H-F Sada; Jennifer Moye Journal: Psychooncology Date: 2019-06-13 Impact factor: 3.894
Authors: Sabine Deprez; Shelli R Kesler; Andrew J Saykin; Daniel H S Silverman; Michiel B de Ruiter; Brenna C McDonald Journal: J Natl Cancer Inst Date: 2018-03-01 Impact factor: 13.506
Authors: Yingchun Zeng; Andy S K Cheng; Ting Song; Xiujie Sheng; Yang Zhang; Xiangyu Liu; Chetwyn C H Chan Journal: BMC Cancer Date: 2017-11-28 Impact factor: 4.430